Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. https://doi.org/10.1016/S2213-8587(17)30319-4. (Epub 2017 Nov 9 PMID: 29129575).

Article  PubMed  CAS  Google Scholar 

Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33. https://doi.org/10.1210/jc.2013-2805. (Epub 2013 Sep 20 PMID: 24057288).

Article  PubMed  CAS  Google Scholar 

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. https://doi.org/10.1210/jc.2015-4061. (Epub 2016 Mar 2 PMID: 26934393).

Article  PubMed  CAS  Google Scholar 

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3:768–74. https://doi.org/10.1001/jamacardio.2018.2003.

Article  PubMed  PubMed Central  Google Scholar 

Köhler A, Sarkis AL, Heinrich DA, Müller L, Handgriff L, Deniz S, Schneider H, Künzel H, Ladurner R, Reincke M, Adolf C. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study. Eur J Endocrinol. 2021;185(5):663–72. https://doi.org/10.1530/EJE-21-0018. (PMID: 34468397).

Article  PubMed  Google Scholar 

Wu VC, Wang SM, Huang KH, Tsai YC, Chan CK, Yang SY, Lin LY, Chang CC, Lu CC, Lin YH, Chen YM, Chueh JS. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol. 2021;186(2):195–205. https://doi.org/10.1530/EJE-21-0836. (PMID: 34851859).

Article  PubMed  Google Scholar 

Mansur A, Vaidya A, Turchin A. Using renin activity to guide mineralocorticoid receptor antagonist therapy in patients with low renin and hypertension. Am J Hypertens. 2023. https://doi.org/10.1093/AJH/HPAD032.

Article  PubMed  PubMed Central  Google Scholar 

Puar TH, Cheong CK, Foo RSY, Saffari SE, Tu TM, Chee MR, Zhang M, Ng KS, Wong KM, Wong A, Ng FC, Aw TC, Khoo J, Gani L, King T, Loh WJ, Soh SB, Au V, Tay TL, Tan E, Mae L, Yew J, Tan YK, Tong KL, Lee S, Chai SC. Treatment of primary aldosteronism and reversal of renin suppression improves left ventricular systolic function. Front Endocrinol (Lausanne). 2022;30(13): 916744. https://doi.org/10.3389/fendo.2022.916744.PMID:35846272;PMCID:PMC9279860.

Article  Google Scholar 

Katsuragawa S, Goto A, Shinoda S, Inoue K, Nakai K, Saito J, Nishikawa T, Tsurutani Y. Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism. Hypertension. 2023;80(9):1909–20. https://doi.org/10.1161/HYPERTENSIONAHA.123.21096. (Epub 2023 Jul 14 PMID: 37449450).

Article  PubMed  CAS  Google Scholar 

Ueda T, Tsurutani Y, Osada J, Inoue K, Hoshino Y, Ono M, Nakai K, Saito J, Yumoto K, Nishikawa T. Comparison of echocardiographic changes between surgery and medication treatment in patients with primary aldosteronism. J Am Heart Assoc. 2022;11(13): e023813. https://doi.org/10.1161/JAHA.121.023813. (Epub 2022 Jun 29. PMID: 35766291; PMCID: PMC9333367).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51–9. https://doi.org/10.1016/S2213-8587(17)30367-4.

Article  PubMed  Google Scholar 

Yoshida Y, Fujiki R, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, Mori Y, Matsuda N, Noguchi T, Nakama H, Okamoto M, Gotoh K, Masaki T, Shibata H. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: the potential importance of post-treatment plasma renin levels. Hypertens Res. 2023;46(1):100–7. https://doi.org/10.1038/s41440-022-01045-5. (Epub 2022 Oct 14 PMID: 36229529).

Article  PubMed  CAS  Google Scholar 

Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016;101(11):3989–96. https://doi.org/10.1210/jc.2016-1963.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen SY, Chen JY, Huang WC, Puar THK, Chin Kek P, Chueh JS, Lin YH, Wu VC, Study Group T. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur J Endocrinol. 2022;187(6):S47–58. https://doi.org/10.1530/EJE-22-0375. (PMID: 36315466).

Article  PubMed  CAS  Google Scholar 

Araujo-Castro M, Paja Fano M, González Boillos M, Pla Peris B, Pascual-Corrales E, García Cano AM, Parra Ramírez P, Rojas-Marcos PM, Ruiz-Sanchez JG, Vicente Delgado A, Gómez Hoyos E, Ferreira R, García Sanz I, Recasens Sala M, Barahona San Millan R, Picón César MJ, Díaz Guardiola P, García González JJ, Perdomo CM, Manjón Miguélez L, García Centeno R, Percovich JC, Rebollo Román Á, Gracia Gimeno P, Robles Lázaro C, Morales-Ruiz M, Hanzu FA. Adrenal venous sampling in primary aldosteronism: experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register). Endocrine. 2022;78(2):363–72. https://doi.org/10.1007/s12020-022-03122-8.

Article  PubMed  CAS  Google Scholar 

Araujo-Castro M, Paja Fano M, González Boillos M, Pla Peris B, Pascual-Corrales E, García Cano AM, Parra Ramírez P, Rojas-Marcos PM, Ruiz-Sanchez JG, Vicente Delgado A, Gómez Hoyos E, Ferreira R, García Sanz I, Díaz Guardiola P, García González JJ, Perdomo CM, Morales M, Hanzu FA. Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry. Endocrine. 2022;76(3):687–96. https://doi.org/10.1007/s12020-022-03029-4. (Epub 2022 Mar 11 PMID: 35275344).

Article  PubMed  CAS  Google Scholar 

Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M, Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5(9):689–99. https://doi.org/10.1016/S2213-8587(17)30135-3. (Epub 2017 May 30. PMID: 28576687; PMCID: PMC5572673).

Article  PubMed  PubMed Central  Google Scholar 

Bernini G, Bacca A, Carli V, Carrara D, Materazzi G, Berti P, Miccoli P, Pisano R, Tantardini V, Bernini M, Taddei S. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Investig. 2012;35(3):274–80. https://doi.org/10.3275/7611. (Epub 2011 Mar 21 PMID: 21422805).

Article  CAS  Google Scholar 

Kline GA, Pasieka JL, Harvey A, So B, Dias VC. Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. Ann Surg Oncol. 2013;20(7):2274–8. https://doi.org/10.1245/s10434-013-2871-3.

Article  PubMed  CAS  Google Scholar 

Wu VC, Peng KY, Hu YH, Chang CC, Chan CK, Lai TS, Lin YH, Wang SM, Lu CC, Liu YC, Tsai YC, Chueh JS. Circulating plasma concentrations of ACE2 in primary aldosteronism and cardiovascular outcomes. J Clin Endocrinol Metab. 2022;107(12):3242–51. https://doi.org/10.1210/clinem/dgac539. (PMID:36125178;PMCID:PMC9494503).

Article  PubMed  Google Scholar 

Collaboration BPLTT. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625–36. https://doi.org/10.1016/S0140-6736(21)00590-0. (Erratum.In:Lancet.2021May22;397(10288):1884).

Article  Google Scholar 

Nomura M, Kurihara I, Itoh H, Ichijo T, Katabami T, Tsuiki M, Wada N, Yoneda T, Sone M, Oki K, Yamada T, Kobayashi H, Tamura K, Ogawa Y, Inagaki N, Yamamoto K, Otsuki M, Yabe D, Izawa S, Takahashi Y, Suzuki T, Yasoda A, Tanabe A, Naruse M, JPAS/JRAS Study Group. Association of cardiovascular disease risk and changes in renin levels by mineralocorticoid receptor antagonists in patients with primary aldosteronism. Hypertens Res. 2022;45(9):1476–85. https://doi.org/10.1038/s41440-022-00960-x. (Epub 2022 Jun 28. PMID: 35764671).

Article  PubMed  CAS  Google Scholar 

Gulati A. Vascular endothelium and hypovolemic shock. Curr Vasc Pharmacol. 2016;14(2):187–95. https://doi.org/10.2174/1570161114666151202210221.

Article  PubMed  CAS  Google Scholar 

Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25(4):292–9. https://doi.org/10.1016/j.ehj.2003.10.030. (PMID: 14984917).

Article  PubMed  CAS  Google Scholar 

Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J. 2007;28(21):2644–52. https://doi.org/10.1093/eurheartj/ehm399. (Epub 2007 Sep 25 PMID: 17895253).

Article  PubMed  CAS  Google Scholar